Bullfrog AI provides update on collaboration with Eleison

BullFrog AI (BFRG) Holdings provided an update on its collaboration with Eleison Pharmaceuticals. To support this collaboration, BullFrog AI developed a new data ingestion module, purpose-built to handle the scale and complexity of Eleison’s historical clinical data. Originally created to convert more than 10,000 pages of clinical trial PDFs into an OMOP-standardized dataset for Eleison, the module proved so effective that it has since become a standalone commercial offering of BullFrog AI called bfPREP. Following ingestion, BullFrog AI applied feature engineering and AI-enhanced curation to extend the dataset, categorizing diseases, medications, lesion descriptors, and normalizing free text into structured fields. Using a layered approach, where automation handles repeatable tasks and human reviewers ensure accuracy, the Company was able to rapidly scale data preparation while maintaining the integrity and nuance required for clinical decision-making. The structured dataset was then deployed into bfLEAP, BullFrog AI’s core analytics engine, to identify data-driven patient subgroups ahead of randomization. These insights may inform both trial design and market positioning, as they illuminate patient segments most likely to benefit from Eleison’s therapies. Encouraged by the progress, BullFrog AI and Eleison are preparing a joint scientific submission to an upcoming oncology conference, which management believes will further validate the commercial value of the Company’s AI platforms. In addition, the two companies are exploring further collaboration through a second contract for additional collaboration work.